Sticking Point: Novartis Menveo Vaccine Delayed By FDA Request for Info
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis has suffered yet another setback over Menveo, its meningococcal meningitis vaccine, thanks to an FDA request for additional information about unspecified clinical and manufacturing issues